Emily Freeman

Postdoctoral Fellow

Email Emily

Dr. Emily Freeman completed her PhD from the University of Ottawa under the supervision of Dr. Kyle Cowan at the Children’s Hospital of Eastern Ontario. Here she discovered a sex-dependant role for the small molecule channel Pannexin 1 in healthy skeletal muscle and found it to be a novel therapeutic target for Duchenne muscular dystrophy. Previously she completed her MSc while working with Dr. Michael Rudnicki at the Ottawa Hospital Research Institute (2019) and her BSc in biology at Brock University in St. Catharines Ontario (2016). She is currently apart of the science to business network Ottawa chapter where she sits as an Event support Associate.

 

Emily has joined the Lochmüller as a Post-Doctoral fellow where she hopes to use patient-derived stem cells to discover new drug therapies for myotonic dystrophy.

Emily Freeman profile picture

Read more about Emily

LinkedIn profile
ResearchGate profile

Recent publications

Freeman, E, Langlois, S, Leyba, MF, Ammar, T, Léger, Z, McMillan, HJ et al.. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice. Skelet Muscle. 2024.14 (1)8 PMID:38671506

Freeman, E, Langlois, S, Scott, K, Ravel-Chapuis, A, Jasmin, BJ, Cowan, KN et al.. Sex-dependent role of Pannexin 1 in regulating skeletal muscle and satellite cell function. J Cell Physiol. 2022.237 (10)3944-3959 PMID:35938715

Langlois S, St-Pierre ME, Holland SH, Xiang X, Freeman E, Mohamed H, Cem Dural A, Hammad A, Karami S, van de Panne C, Cowan K. Inhibition of PANX1 Channels Reduces the Malignant Properties of Human High-Risk Neuroblastoma. J. Cancer 2023; 14(5): 689-706. doi:10.7150/jca.79552

See more on PubMed